ASCO 2023 | ATTRACTION-5: nivo + chemo as postoperative adju treatment for pathological stage III G/GEJ cancer

Masanori Terashima, MD, PhD, FACS, Shizuoka Cancer Center, Nagaizumi, Japan, talks on the Phase III ATTRACTION-5 (NCT03006705) study evaluating the efficacy of nivolumab plus chemotherapy as postoperative adjuvant treatment for patients with pathological stage III gastric or gastroesophageal junction (G/GEJ) cancer who had undergone D2 or more extended gastrectomy. The study enrolled 755 patients who were randomly assigned to receive either nivolumab plus chemotherapy or placebo plus chemotherapy. The primary endpoint of centrally-assessed relapse-free survival (RFS) was not met, with similar 3-year RFS rates observed in both arms. The completion rate of postoperative adjuvant treatment was lower in the nivolumab plus chemotherapy arm compared to the placebo plus chemotherapy arm. The incidence of grade ≥3 treatment-related adverse events was higher in the nivolumab plus chemotherapy arm. The study concluded that nivolumab plus chemotherapy did not demonstrate superiority over standard adjuvant chemotherapy in terms of RFS in this patient population. The safety profile of nivolumab plus chemotherapy was consistent with previous knowledge. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.